Showing 51-60 of 3104 results for "".
- Study Compares FUS Unilateral Thalamotomy vs FUS Subthalamotomy in People with Medication Refractory Tremorhttps://practicalneurology.com/news/study-compares-fus-unilateral-thalamotomy-vs-fus-subthalamotomy-in-people-with-medication-refractory-tremor/2470600/Research presented at the 2024 International Congress of Parkinson’s Disease and Movement Disorders compared the effects of unilateral focused ultrasound subthalamotomy (FUS-STN) with unilateral focused ultrasound of the ventral intermediate thalamic nucleus (FUS-Vim) in participants with m
- FDA Clears Wearable Electrophysiological Monitoring Patch to Record EEG, EOG, EMG, and EKG Datahttps://practicalneurology.com/news/fda-clears-wearable-electrophysiological-monitoring-patch-to-measure-eeg-eog-emg-and-ekg-signals/2470409/The Food and Drug Administration (FDA) has granted 510(k) clearance to Smart Skin (X-trodes System M; X-trodes, Tel Aviv, Israel). Smart Skin is a wireless wearable system for medical-grade electrophysiological monitoring for at-home use, available as a dry-printed multi-modal electrode patch. Th
- Access to Care and Hispanic Cultural Attitudes Regarding Epilepsyhttps://practicalneurology.com/news/access-to-care-and-hispanic-cultural-attitudes-regarding-epilepsy/2469772/Research on attitudes and perceptions toward health care amongst diverse groups of people is required to address social determinants of health that lead to health care disparities in the US. Findings from virtual focus groups of people with epilepsy, living in Texas and California and reporting M
- Perampanel as Monotherapy or First Adjunctive Therapy Effectively Reduced Seizures in a Phase 4 Studyhttps://practicalneurology.com/news/perampanel-as-monotherapy-or-first-adjunctive-therapy-effectively-reduced-seizures-in-a-phase-4-study/2469771/In the ELEVATE study (NCT03288129), 63% (34/54) of individuals, age 4 or more, who were treated with perampanel (Fycompa; Eisai, Woodcliff Lake, NJ) as monotherapy or a first adjunctive therapy continued treatment over a 12-month period. The retention rate was higher when perampanel was used as m
- Efgartigimod Treatment Improves Function for People With Generalized Myasthenia Gravishttps://practicalneurology.com/news/efgartigimod-treatment-improves-function-for-people-with-generalized-myasthenia-gravis/2469618/Efgartigimod (Argenx, Boston, MA) vs placebo treatment of acetylcholine receptor-antibody positive (antiAChR+) generalized myasthenia gravis (gMG) resulted in clinical improvement for 67.7% vs 29.7% of those treated (P<.0001). Activities of daily living were measured with the M
- New No-Cost Course for Professionals in Stroke Centers with High-Volume of COVID-19https://practicalneurology.com/news/new-no-cost-course-for-professionals-in-stroke-centers-with-high-volume-of-covid-19/2469417/The American Heart Association is offering an education course for healthcare professionals on stroke care with considerations for additional protocols and care practices that come with the COVID-19 pandemic. This course is made possible by support from the Leona B. and Harry M. H
- Tauroursodeoxycholic Acid /Sodium Phenylbutyrate Decreased Rate of Decline in ALShttps://practicalneurology.com/news/tauroursodeoxycholic-acid-sodium-phenylbutyrate-decreased-rate-of-decline-in-als/2469369/Results of a pivotal phase 2/3 clinical trial (NCT03127514) evaluating tauroursodeoxycholic acid (TUDCA) /sodium phenylbutyrate (PB) combination (AMX0035; Amylyx Pharmaceuticals, Cambridge, MA) for treatment of amyotrophic lateral sclerosis (ALS) has been published in the New England Journal of M
- FDA Rejects Application for Gene Therapy for Hunter Syndromehttps://practicalneurology.com/news/fda-rejects-application-for-gene-therapy-for-hunter-syndrome/2485648/The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for RGX-121 (clemidsogene lanparvovec; REGENXBIO, Rockville, MD), meaning that, at this time, the FDA will not approve the investigational gene therapy for mucopolysaccha
- Director of the National Institute of Neurological Disorders and Stroke Oustedhttps://practicalneurology.com/news/director-of-the-national-institute-of-neurological-disorders-and-stroke-ousted/2485145/The contract for Walter Koroshetz, MD, as Director of the National Institute of Neurological Disorders and Stroke (NINDS) has not been renewed, ending his leadership of the institute after 10 years. Dr. Koroshetz’s departure comes despite a positive internal review and a recommendation for reappo
- Prof. Ludwig Kappos Recognized for His Lifetime Achievement in Multiple Sclerosis Research at ECTRIMS 2025https://practicalneurology.com/news/prof-ludwig-kappos-recognized-for-his-lifetime-achievement-in-multiple-sclerosis-research-at-ectrims-2025/2483561/At the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Ludwig Kappos, MD, Dipl Psych, FEAN, FAAN was recognized as the recipient of the 2025 Charcot Award. According to ECTRIMS, the Charcot Award, which is presented by the Multiple Sclerosis Int